Frequently Asked Questions
The market is segmented based on , By Drug Type (Emixustat, LBS-008), Diagnosis (Visual Field Testing, Colour Testing, Fundus Photo, Electroretinography (ERG), Optical Coherence Tomography (OCT), Others), Treatment (Dark Sunglasses, Gene Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Stargardts Treatment Market size was valued at USD 165.38 USD Million in 2021.
The Global Stargardts Treatment Market is projected to grow at a CAGR of 30% during the forecast period of 2022 to 2029.
The major players operating in the market include American Macular Degeneration Foundation, Royal National Institute of Blind People, Kubota Pharmaceutical Holdings Co., IVERIC bio, Sanofi, Alkeus Pharmaceuticals, Astellas Pharma , reVision Therapeutics, Lin BioScience, Biogen, F. Hoffmann La Roche AG.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.